Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report earnings per share of ($0.64) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.73). Nektar Therapeutics reported earnings of $0.37 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 273%. The firm is scheduled to issue its next earnings results on Tuesday, November 6th.
On average, analysts expect that Nektar Therapeutics will report full-year earnings of $3.57 per share for the current fiscal year, with EPS estimates ranging from $3.22 to $3.82. For the next fiscal year, analysts forecast that the company will post earnings of ($0.98) per share, with EPS estimates ranging from ($2.69) to $4.42. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.11. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the previous year, the company posted ($0.39) earnings per share. The business’s revenue for the quarter was up 3043.7% compared to the same quarter last year.
In other Nektar Therapeutics news, Director R Scott Greer sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total transaction of $673,900.00. Following the completion of the sale, the director now owns 140,333 shares in the company, valued at $9,457,040.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis L. Winger sold 34,250 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $60.60, for a total transaction of $2,075,550.00. Following the sale, the director now owns 59,875 shares of the company’s stock, valued at approximately $3,628,425. The disclosure for this sale can be found here. Insiders sold 96,000 shares of company stock worth $5,825,680 over the last ninety days. 4.31% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. Asset Management One Co. Ltd. bought a new stake in Nektar Therapeutics during the first quarter valued at $110,000. We Are One Seven LLC bought a new stake in Nektar Therapeutics during the first quarter valued at $118,000. Suntrust Banks Inc. bought a new stake in Nektar Therapeutics during the first quarter valued at $264,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Nektar Therapeutics during the second quarter valued at $137,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Nektar Therapeutics during the second quarter valued at $142,000. Hedge funds and other institutional investors own 92.20% of the company’s stock.
Shares of NASDAQ NKTR traded up $1.01 during trading on Monday, reaching $48.91. 2,001,546 shares of the stock were exchanged, compared to its average volume of 3,167,571. Nektar Therapeutics has a twelve month low of $22.75 and a twelve month high of $111.36. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. The stock has a market cap of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Recommended Story: Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.